From: Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia
Disease | Kinase target | Approved inhibitors |
---|---|---|
Chronic myeloid leukemia (CML) | BCR-ABL1 | Imatinib, dasatinib, nilotinib, bosutinib, ponatinib |
Ph acute lymphocytic leukemia (ALL) | BCR-ABL1 | Imatinib, dasatinib, nilotinib, bosutinib, ponatinib |
Mastocytosis | KIT | Imatinib |
Hypereosinophilic syndrome (HES) | FIP1L1-PDGFRα | Imatinib |
Chronic eosinophilic leukemia (CEL) | FIP1L1-PDGFRα | Imatinib |
PDGFRβ | Imatinib | |
Gastrointestinal stromal tumors (GIST) | KIT; PDGFRα | Imatinib |
Melanoma | BRAF | Vemurafenib |
Non-small cell lung cancer (NSCLC) | EGFR1 | Gefinitinib, erlotinib |
ALK | Crizotinib, ceritinib | |
Chronic lymphocytic leukemia (CLL) | BTK | Ibrutinib |
Mantle cell lymphoma | BTK | Ibrutinib |